We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04525183
Recruitment Status : Active, not recruiting
First Posted : August 25, 2020
Last Update Posted : October 14, 2022
Sponsor:
Collaborators:
AstraZeneca
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Alexi A. Wright, Dana-Farber Cancer Institute

Brief Summary:
This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Fatigue Coping Behavior Coping Skills Behavioral: Enhanced Usual Care (EOC) Behavioral: REVITALIZE ACT Intervention Not Applicable

Detailed Description:

This is a two-arm, multicenter pilot randomized controlled trial to compare the feasibility, acceptability, and preliminary efficacy of REVITALIZE, a 6-week Acceptance and Commitment Therapy (ACT) telehealth intervention vs. enhanced usual care (EUC) in fatigued patients with ovarian cancer on maintenance PARPi.

The intervention is called REVITALIZE, and it is a structured, skills-based intervention for providing support, knowledge, and skills for coping with fatigue. This type of intervention has been used in other studies to treat symptoms such as pain, migraines, or worry. This research is being done to develop this program at the Dana-Farber Cancer Institute and the University of Pennsylvania's Abramson Cancer Center, and to get patient feedback on the telehealth intervention to improve it for a future study. The study is also making a preliminary determinations as to whether REVITALIZE does improve psychological flexibility and fatigue-related interference and reduce fatigue, psychological distress, and fear of cancer recurrence, while improving overall quality of life (QOL).

The study will pre-pilot the REVITALIZE intervention in up to 5 patients at the Dana-Farber Cancer Institute (DFCI). This run-in phase serves to test and refine the newly developed 6-week ACT intervention in a smaller sample size prior to initiating the randomized control trial (RCT) portion of the study. After the ACT intervention has been tested and refined, the study will enroll and randomize 40 fatigued patients with advanced ovarian cancer on maintenance PARPi at Dana-Farber Cancer Institute and the Abramson Cancer Center at the University of Pennsylvania.

Participants will be randomized to receive either a 6-week ACT intervention or enhanced usual care (educational materials). The study anticipates enrolling approximately 20 patients at each site, and 20 patients will be enrolled to each study arm.

It is expected participants will remain in the study for the duration of the intervention and follow-up assessments, which is approximately 3 months.

The Funding Organization for this study is the National Comprehensive Cancer Network (NCCN) and the Research Funding Provider is AstraZeneca.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
Actual Study Start Date : December 2, 2020
Actual Primary Completion Date : July 28, 2022
Estimated Study Completion Date : July 28, 2023


Arm Intervention/treatment
Experimental: Run In

Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study

  • Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE).
Behavioral: REVITALIZE ACT Intervention
Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks

Experimental: Enhanced Usual Care (EUC)
Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
Behavioral: Enhanced Usual Care (EOC)
Educational materials

Experimental: REVITALIZE ACT Intervention
Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly sessions lasting approximately 60-75-minutes over a 6-8 week period, delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
Behavioral: REVITALIZE ACT Intervention
Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks




Primary Outcome Measures :
  1. Enrollment Rate [ Time Frame: Baseline to 12-weeks ]
    Feasibility will be defined as ≥50% approach-to-enrollment rate of participants eligible participants and ≥70% completion of 3-month outcome assessments.

  2. Retention Rate [ Time Frame: 12 weeks ]
    Acceptability will be defined as ≤20% of participants reporting high study burden and ≤20% withdrawing from the study.

  3. Fatigue Change [ Time Frame: Change in fatigue from baseline to 8 weeks and baseline to 12 weeks ]
    Changes in fatigue will be measured using the Fatigue Symptom Inventory scale, a 14-item, 11-point rating scale developed to assess subjective fatigue, in which higher scores indicate greater fatigue.


Secondary Outcome Measures :
  1. Emotional Distress [ Time Frame: Change in emotional distress from baseline to 8 weeks and baseline to 12 weeks ]
    Measured by Generalized Anxiety Disorder 7 (GAD-7) scale, a 7-item measure assessing anxiety severity on a 4-point scale (0 = not at all, to 3 = nearly every day). GAD-7 total score for the seven items ranges from 0 to 21. Higher scores indicate more moderate to severe anxiety.

  2. Emotional Distress [ Time Frame: Change in emotional distress from baseline to 8 weeks and baseline to 12 weeks ]
    Measured by the Patient Health Questionnaire-8 (PHQ-8) scale, an 8-item measure assessing depression on a 4-point Likert scale (0 = not at all, to 3 = nearly every day). Higher scores indicate more severe depression.

  3. Fear of Cancer Recurrence (FCRI), [ Time Frame: Baseline to 8- and 12-weeks ]

    Measured by the 42-item Fear of Cancer Recurrence Inventory (FCRI) scale, which evaluates 7 aspects associated with FCR: 1) triggers, 2) severity, 3) psychological distress), 4) functioning impairments, 5) insight, 6) reassurance, and 7) coping strategies.

    Each item is rated on a Likert scale ranging from 0 ('not at all' or 'never) to 4 ('a great deal' or 'all the time'). A total score can be obtained for each subscale, and for the total scale by summing item ratings. Higher scores indicate higher levels of FCR.


  4. Physical well-being [ Time Frame: Baseline to 8- and 12-weeks ]
    Measured by the Functional Assessment of Cancer Therapy-Ovarian Cancer FACT-O scale.

  5. Social/family well-being [ Time Frame: Baseline to 8- and 12-weeks ]
    Measured by the Functional Assessment of Cancer Therapy-Ovarian Cancer FACT-O, scale. Items scored on a 5-point Likert Scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Scores range for each subscale. Higher scores indicate better QOL. Social/family well-being (score range 0-28).

  6. Emotional well-being [ Time Frame: Baseline to 8- and 12-weeks ]
    Measured by the Functional Assessment of Cancer Therapy-Ovarian Cancer FACT-O scale. Items scored on a 5-point Likert Scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Scores range for each subscale. Higher scores indicate better QOL. Emotional well-being (score range 0-28).

  7. Functional well-being [ Time Frame: Baseline to 8- and 12-weeks ]
    Measured by the Functional Assessment of Cancer Therapy-Ovarian Cancer FACT-O scale. Items scored on a 5-point Likert Scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). Scores range for each subscale. Higher scores indicate better QOL. Functional well-being (score range 0-28).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women ≥18 years of age who have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Receiving PARPI inhibitors for ≥ 2 months.
  • Able to read/speak English.
  • Have an Eastern Oncology Group (ECOG) performance of 0-2.
  • Report moderate-severe fatigue in the past week (average score ≥4 on a Fatigue Symptom Inventory scale of 0-10)

Exclusion Criteria:

  • Patients with an untreated clinical condition or comorbid illness (e.g. anemia, hypothyroidism) that could explain their fatigue.
  • Patients with chronic severe fatigue that pre-dates their use of PARPi.
  • The following special populations will be excluded from this research:

    • Adults unable to consent
    • Individuals who are not yet adults (infants, children, teenagers)
    • Pregnant women
    • Prisoners

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04525183


Locations
Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Dana-Farber Cancer Institute
AstraZeneca
National Comprehensive Cancer Network
Investigators
Layout table for investigator information
Principal Investigator: Alexi A Wright, MD, MPH Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Alexi A. Wright, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT04525183    
Other Study ID Numbers: 20-285
First Posted: August 25, 2020    Key Record Dates
Last Update Posted: October 14, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexi A. Wright, Dana-Farber Cancer Institute:
Ovarian Cancer
Fatigue
Coping Behavior
Coping Skills
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fatigue
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type